NiQuitin Clear transdermal patch

NiQuitin is a globally recognized brand specializing in Nicotine Replacement Therapy (NRT) products, designed to support individuals in their journey to quit smoking. Originally developed and launched by the pharmaceutical giant GlaxoSmithKline (GSK) in the early 1990s, the brand established itself as a leader in transdermal nicotine delivery systems. The 'Clear' patch technology was an innovation aimed at providing a discreet, see-through alternative to traditional opaque patches.

Following a major global asset swap and joint venture formation between GSK and Novartis in 2015, the NiQuitin brand was divested to Perrigo Company plc to satisfy regulatory requirements. Perrigo, a leading provider of over-the-counter (OTC) self-care products, now manages the brand's global operations, excluding certain markets like the United States where the same technology is marketed under different names.

Manufacturing for NiQuitin patches is primarily concentrated in specialized pharmaceutical facilities in Europe, notably Italy (Perrigo Italia) and France, ensuring high standards of quality and controlled nicotine release. The product is distributed locally in Ireland by Chefaro Ireland DAC, a subsidiary of Perrigo, which oversees compliance and safety monitoring for the Irish market.